John Stellwagen - Concepedia

Author

John Stellwagen

Amgen (United States)

Also Known As

John C. Stellwagen, John Stellwagen, Stellwagen, John

Publications

507

Citations

H-Index

Concepts

All Affiliations

Amgen (United States)GlaxoSmithKline (United States)Research Triangle Park Foundation

About

John Stellwagen is an author at Amgen (United States) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	426
2	Cell Biology	3	3	318
3	Natural Sciences	1	1	36
4	Biochemistry	1	1	36
5	Chemical Biology	1	1	36

John Stellwagen

Publications

506

Citations

H-Index

Page 1

	Year	Citations
Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors Tara Rheault, John Stellwagen, George M. Adjabeng, ACS Medicinal Chemistry Letters B-raf-driven TumorsAntitumor ActivityHyperactive SignalingTumor BiologyMedicinal Chemistry	2013	253
Sulfonamides as Selective Na<sub>V</sub>1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity Russell F. Graceffa, Alessandro A. Boezio, Jessica Able, Journal of Medicinal Chemistry	2017	66
Abstract B88: A selective Raf kinase inhibitor induces cell death and tumor regression of human cancer cell lines encoding B-RafV600E mutation Sylvie Laquerre, Marc R. Arnone, Katherine G. Moss, Molecular Cancer Therapeutics Tumor RegressionB-rafv600e MutationCell DeathSelectivity Towards B-rafCancer Biology	2009	54
The Discovery and Optimization of a Novel Class of Potent, Selective, and Orally Bioavailable Anaplastic Lymphoma Kinase (ALK) Inhibitors with Potential Utility for the Treatment of Cancer Richard T. Lewis, Christiane Bode, Deborah M. Choquette, Journal of Medicinal Chemistry Pharmaceutical ChemistryAnaplastic Lymphoma KinaseTumor BiologyMedicinal ChemistryOncology	2012	43
Discovery and optimization of potent and selective imidazopyridine and imidazopyridazine mTOR inhibitors Emily A. Peterson, Alessandro A. Boezio, Paul S. Andrews, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryDrug TargetBiochemistryMedicineNatural Sciences	2012	36
Development of potent B-RafV600E inhibitors containing an arylsulfonamide headgroup John Stellwagen, George M. Adjabeng, Marc R. Arnone, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryPotent B-rafv600e InhibitorsMedicineRational Drug DesignDrug Development	2011	29
Identification of Structurally Novel KRAS<sup>G12C</sup> Inhibitors through Covalent DNA-Encoded Library Screening David Huang, Francesco Manoni, Zhen Sun, Journal of Medicinal Chemistry	2025	14
Abstract 1795: Characterization of a novel series of potent, selective inhibitors of wild type and mutant/fusion anaplastic lymphoma kinase Keith Wilcoxen, Rachael Brake, Doug Saffran, Cancer Research Tyrosine KinaseMetastatic NsclcPathologySelective InhibitorsCancer Biology	2012	11

Page 1